UNSPSC 51333404: Eltoprazine

This classification denotes a serotonin agonist with the molecular formula C12H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 510M006KO6, chemically known as 1-(1,4-benzodioxan-5-yl)piperazine but generally known as eltoprazine, which bears US NIH Compound Identifier 65853. European Medicines Agency schedules Eltoprazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06496MIG.

UNSPSC 51333404 Eltoprazine is a Commodity code nominally designating a specific pharmaceutical active ingredient, but recent state and local solicitations tagged with this code do not reflect purchases of eltoprazine itself. Instead, the code appears in procurement activity for naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals with OTC products, and direct-to-manufacturer prescription programs — categories that diverge significantly from the code's nominal scope. State and local governments are using this code to solicit pharmaceutical supply contracts, emergency response medications, and pharmacy benefit program services across health departments, cooperative purchasing alliances, and state HHS commissions. The mix of issuing bodies includes county health authorities (Seminole County, Florida), state-level cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance), and state health and human services departments (Texas HHS Commission).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026, with response due July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with response due March 26, 2026, targeting availability by July 1, 2026 across participating state and local facilities; and the Texas HHS Commission's RFI for direct-to-manufacturer prescription program capabilities, posted April 3, 2026. The mismatch between the code's name and the work actually being solicited suggests either a data-entry error in state procurement systems or a broadening of the code's practical application to cover general pharmaceutical procurement — either way, vendors evaluating this code should verify alignment with their actual product or service offering before investing in pursuit.